RxDoctor Payments Data

Justin Anderson, NP

Family · Bainbridge, GANPI 1023494135

Payments from drug & device makers

$3,123in general payments, 2019–2025

Across 151 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$820
  • Neurocrine Biosciences, Inc.$462
  • Johnson & Johnson$428
  • Teva Pharmaceuticals USA, Inc.$421
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$358
  • Otsuka America Pharmaceutical, Inc.$249
  • plus $384 from 5 others

What the payments were for

  • Food & beverage$3,02597%
  • Education$983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,123 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$11,500
Medicare patients
72
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole132$388,583
Invega SustennaPaliperidone Palmitate52$164,853
VraylarCariprazine Hcl78$111,465
Lurasidone Hcl77$27,204
LybalviOlanzapine/Samidorphan Malate13$22,664
Aripiprazole252$9,881
Quetiapine Fumarate622$6,427
Ziprasidone Hcl85$3,856
Duloxetine Hcl131$3,839
Benztropine Mesylate357$3,474
Haloperidol Decanoate71$3,025
Buspirone Hcl327$2,861
Olanzapine179$2,777
Trazodone Hcl240$2,748
Hydroxyzine Pamoate225$2,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$249$388,583132 claims
Johnson & JohnsonInvega Sustenna$428$164,85352 claims
AbbVieVraylar$820$111,46578 claims
Alkermes, Inc.Lybalvi$149$22,66413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Bainbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →